{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Maglalang PD"],"funding":["Eunice Kennedy Shriver National Institute of Child Health and Human Development","NICHD NIH HHS"],"pagination":["885-899"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11225543"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["63(6)"],"pubmed_abstract":["<h4>Background</h4>Levetiracetam is an antiseizure medication used for several seizure types in adults and children aged 1 month and older; however, due to a lack of data, pharmacokinetic (PK) variability of levetiracetam is not adequately characterized in certain populations, particularly neonates, children younger than 2 years of age, and children older than 2 years of age with obesity.<h4>Objective</h4>This study aimed to address the gap by leveraging PK data from two prospective standard-of-care pediatric trials (n = 88) covering an age range from 1 month to 19 years, including those with obesity (64%), and applying a physiologically based PK (PBPK) modeling framework.<h4>Methods</h4>A published PBPK model of levetiracetam for children aged 2 years and older was extended to pediatric p"],"journal":["Clinical pharmacokinetics"],"pubmed_title":["Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population."],"pmcid":["PMC11225543"],"funding_grant_id":["HHSN275201000003C","R01 HD096435","5R01HD096435","HHSN275201000003I","T32 HD104576","R01 HD102949"],"pubmed_authors":["West L","McCann S","Clark K","Jefferson G","Milleson C","Simone G","Craven S","Talbert J","Parsons A","John R","Mourani P","Capozzi T","Dix M","Taylor L","Fearn L","Shakespear K","Kennel P","Taylor J","Vitou B","James L","Pohl D","Hornik C","Tuttle A","Eubanks S","Kowal K","Finkelstein Y","Tiedge H","McMillan H","Nielsen C","Gerhardt B","Gonzalez D","Oldham M","Wrenn S","Rathore M","Mottes T","Taravath S","Kearns GL","Desmarasis D","Lacaze T","Klipner K","Shankar K","Hornik CD","Blackford M","Speicher D","Howard L","Malone K","Lapid A","Howard E","Odero N","Al-Uzri A","Deville J","Baez A","Harper C","Berkovitch M","Denne S","Grzesek K","Rutebemberwa A","Kernen K","Ralston K","Yogev R","Poff S","Autmizguine J","Massicotte C","Myer D","Ann DP","Shiloh-Malawsky Y","Kohn E","Konow C","Muller WJ","Reed M","Adams R","Wiseheart M","Bradley G","Ieradi S","Kirby C","Zimmerman K","Hornik CP","Anthony H","Baisden N","O'Connor K","Goldstein S","Delmore P","Poindexter B","Van K","Lang E","Kost B","Sinha J","Stryjewski G","Muller W","Sierra Y","Lakhotia A","Michael A","Traisman B","Sokol G","Alger F","Watt K","Sherwin C","Sargent J","Murchison B","Laughon M","Comings J","Salman Y","Zemek R","Mariconti A","Beci R","Goldenberg N","Chen L","Anand R","Meyer M","Wade K","Sroka P","Dixit S","Deschenes J","Terrell T","Sund Z","Martinez M","Litalien C","Steinbeiss M","Chen JY","Jolly M","Bernhardt J","Opel K","Benjamin DK","Hodge A","Petersen L","Toltzis P","Maglalang PD","Paul IM","Blanks T","Filar L","Thoma K","Sullivan J","Arnold S","Perrin EM","Arnold P","Shimizu J","Alderman C","Simeon T","Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee","Harward M","Walker A","Drake A","DePaoli B","Joshi S","Lemon E","Rumantir M","Hart M","Rosen P","Tasi C","Perry J","Perez R","Goldblatt E","Abdel-Rahman S","Burmester J","Cermak J","Joshi C","Narus J","Halstenson G","Payne E","Hansberry D","Borges A","Brown K","Anderson C","Dumitrascu M","Spigarelli M","Lague V","Moore A","Edginton A","DiDomenico D"],"additional_accession":[]},"is_claimable":false,"name":"Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population.","description":"<h4>Background</h4>Levetiracetam is an antiseizure medication used for several seizure types in adults and children aged 1 month and older; however, due to a lack of data, pharmacokinetic (PK) variability of levetiracetam is not adequately characterized in certain populations, particularly neonates, children younger than 2 years of age, and children older than 2 years of age with obesity.<h4>Objective</h4>This study aimed to address the gap by leveraging PK data from two prospective standard-of-care pediatric trials (n = 88) covering an age range from 1 month to 19 years, including those with obesity (64%), and applying a physiologically based PK (PBPK) modeling framework.<h4>Methods</h4>A published PBPK model of levetiracetam for children aged 2 years and older was extended to pediatric p","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2026-06-02T20:33:30.852Z","creation":"2026-05-27T03:07:49.342Z"},"accession":"S-EPMC11225543","cross_references":{"pubmed":["38814425"],"doi":["10.1007/s40262-024-01367-2"]}}